Frequency and Significance of Hepatic Involvement in New-Onset Giant Cell Arteritis: A Study of 514 Patients

REFERENCES

1. 1.↵
   1. Dickson ER,
   2. Maldonado JE,
   3. Sheps SG,
   4. Cain JA Jr.

   Systemic giant-cell arteritis with polymyalgia rheumatica, reversible abnormalities of liver function. JAMA 1973 11;224:1496-8.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Sonnenblick M,
   2. Nesher G,
   3. Rosin A.

   Nonclassical organ involvement in temporal arteritis. Semin Arthritis Rheum 1989;19:183-93.

   OpenUrlCrossRefPubMed
3. 3.
   1. Ilan Y,
   2. Ben-Chetrit E.

   Liver involvement in giant cell arteritis. Clin Rheumatol 1993;12:219-22.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Achar KN,
   2. Ashfield RP.

   Gross cholestatic dysfunction in giant cell arteritis. Postgrad Med J 1995;71:59-60.

   OpenUrlFREE Full Text
5. 5.↵
   1. Achar KN,
   2. Al-Alousi SS,
   3. Patrick JP.

   Biliary ultrastructural changes in the liver in a case of giant cell arteritis. Br J Rheumatol 1994;33:161-4.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Ogilvie AL,
   2. James PD,
   3. Toghill PJ.

   Hepatic artery involvement in polymyalgia arteritica. J Clin Pathol 1981;34:769-72.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Gonzalez-Gay MA,
   2. Lopez-Diaz MJ,
   3. Barros S, et al.

   Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine 2005;84:277-90.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Liozon E,
   2. Dumonteil S,
   3. Parreau S, et al.

   Risk profiling for a refractory course of giant cell arteritis: the importance of age and body weight: “risk profiling for GC resistance in GCA”. Semin Arthritis Rheum 2020;50:1252-61.

   OpenUrl
9. 9.↵
   1. Keser G,
   2. Aksu K,
   3. Direskeneli H.

   Discrepancies between vascular and systemic inflammation: an important problem revisited. Rheumatology 2018;57:784-90.

   OpenUrl
10. 10.↵
    1. Cid MC,
    2. Font C,
    3. Oristrell J, et al.

    Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998;41:26-32.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Ishiguro K,
    2. Yamashita H,
    3. Shimizu Y,
    4. Kaneko H.

    Biomarkers as predicting factors for relapse in polymyalgia rheumatica: the importance of alkaline phosphatase. Rheumatology 2023 April 4 (Epub ahead of print).
12. 12.↵
    1. Hysa E,
    2. Castagna A,
    3. Manzo C.

    Liver involvement in polymyalgia rheumatica and giant cell arteritis. Reumatologia 2020;58:444-5.

    OpenUrl